Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $47.5 million.

  • Beam Therapeutics' Accumulated Expenses fell 18.26% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year decrease of 18.26%. This contributed to the annual value of $47.5 million for FY2024, which is 57.49% down from last year.
  • Per Beam Therapeutics' latest filing, its Accumulated Expenses stood at $47.5 million for FY2024, which was down 57.49% from $111.7 million recorded in FY2023.
  • Beam Therapeutics' 5-year Accumulated Expenses high stood at $111.7 million for FY2023, and its period low was $18.5 million during FY2020.
  • Its 3-year average for Accumulated Expenses is $69.7 million, with a median of $49.9 million in 2022.
  • Per our database at Business Quant, Beam Therapeutics' Accumulated Expenses spiked by 135.14% in 2020 and then crashed by 57.49% in 2024.
  • Yearly analysis of 5 years shows Beam Therapeutics' Accumulated Expenses stood at $18.5 million in 2020, then spiked by 56.64% to $28.9 million in 2021, then spiked by 72.58% to $49.9 million in 2022, then spiked by 123.72% to $111.7 million in 2023, then plummeted by 57.49% to $47.5 million in 2024.